Synthesis of 6-formyl-pyridine-2-carboxylate derivatives and their telomerase inhibitory activities

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 609-612

  Jew, Sang Sup ^a   Park, Boon Saeng ^a   Lim, Doo Yeon ^a   Kim, Myoung Goo ^a   Chung, In Kwon ^b   Kim, Joo Hee ^b   Hong, Chung Il ^c   Kim, Joon Kyum ^c   Park, Hong Jun ^c   Lee, Jun Hee ^c   Park, Hyeung Geun ^a  

^a Seoul National University   (South Korea)

^b Yonsei University   (South Korea)

^c Chong Kun Dang Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO THIOPHENOL ESTER; 6 FORMYL 2 CARBOXYLIC ACID; ANILINE; CAMPTOTHECIN; CARBOXYLIC ACID DERIVATIVE; PHENOL; TELOMERASE; THIOPHENOL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN;

EID: 0037293002     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01041-7     Document Type: Article

References (24)

1. Raymond E., Sun D., Chen S.F., Windle B., von Hoff D.D. Curr. Opin. Biotech. 7:1996;583.
2. (a) Blackburn E.H. Nature. 350:1991;569.
3. (b) Meyne J., Ratliff R.L., Moyzis R.K. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7049.
4. Kipling D. The Telomere. 1995;Oxford University Press, Oxford.
5. (a) Morin G.B. Cell. 59:1989;521.
6. (b) Feng J., Funk W., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.-P., Adams R.R., Chang E., Allsopp R.C., Yu J., Le S., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. Science. 269:1995;1236
7. (c) Meyerson M., Counter C.M., Eaton E.N., Ellison L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., Weinberg R.A. Cell. 90:1997;785.
8. (a) Hamilton S.E., Corey D.R. Chem. Biol. 3:1996;863.
9. (b) Parkinson E.K. J. Cancer. 73:1996;1.
10. (a) Neidle S., Kelland L.R. Anti-Cancer Drug Des. 14:1999;341.
11. (b) Lichtsteiner S.P., Lebkowski J.S., Vasserot A.P. Ann. N.Y. Acad. Sci. 886:1999;1.
12. Wheelhouse R., Sun D., Han H., Han F.X., Hurley L.H. J. Am. Chem. Soc. 120:1998;3261.
13. Shin-ya K., Wierzba K., Matsuo K., Ohtani T., Yamada Y., Furihata K., Hayakawa Y., Seto H. J. Am. Chem. Soc. 123:2001;1262.
14. (a) Perry P.J., Gowan S.M., Reszka A.P., Polucci P., Jenkins T.C., Kelland L.R., Neidle S. J. Med. Chem. 41:1998;3253.
15. (b) Harrison R.J., Gowan S.M., Kelland L.R., Neidle S. Bioorg. Med. Chem. Lett. 9:1999;2463.
16. (c) Perry P.J., Read M.A., Davies R.T., Gowan S.M., Reszka A.P., Wood A.A., Kelland L.R., Neidle S. J. Med. Chem. 42:1999;2679.
17. Heald R.A., Modi C., Cookson J.C., Hutchinson I., Laughton C.A., Gowan S.M., Kelland L.R., Stevens M.F.G. J. Med. Chem. 45:2002;590.
18. Sasaki S., Ehara T., Sakata I., Fujino Y., Harada N., Kimura J., Nakamura H., Maeda M. Bioorg. Med. Chem. Lett. 11:2001;583.
19. Geron, Co. Ltd. US Patent No. 5,767,278.
20. (b) Geron, Co. Ltd. US Patent No. 5,770,613.
21. All compounds gave satisfactory spectroscopic data consistent with the proposed structures.
22. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Caviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Science. 266:1994;2011.
23. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenny S., Boyd M.R. J. Med. Natl. Canc. Inst. 82:1990;1107.
24. 2) × 0.5. The tumors were weighed on the day that the experiments finished. The effects by treatments were represented by the following equation: Inhibition Rate, IR(%)=(1-TWt/TWc) × 100. Where TWt is mean tumor weight (volume) value obtained for the treated group and TWc is mean tumor weight (volume) value obtained for the control group.